CY1120977T1 - Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι - Google Patents

Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι

Info

Publication number
CY1120977T1
CY1120977T1 CY181101308T CY181101308T CY1120977T1 CY 1120977 T1 CY1120977 T1 CY 1120977T1 CY 181101308 T CY181101308 T CY 181101308T CY 181101308 T CY181101308 T CY 181101308T CY 1120977 T1 CY1120977 T1 CY 1120977T1
Authority
CY
Cyprus
Prior art keywords
treatment
gylicogene
storage diseases
storage disease
disease type
Prior art date
Application number
CY181101308T
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120977(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07001091.3A external-priority patent/EP1782825B1/en
Application filed by Univ Duke filed Critical Univ Duke
Publication of CY1120977T1 publication Critical patent/CY1120977T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102Alpha-glucosidase (3.2.1.20)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Περιγράφονται μέθοδοι θεραπείας της ασθένειας αποθήκευσης γλυκογόνου τύπου II, με τη χορήγηση όξινης α-γλυκοσιδάσης, όπως επίσης συνθέσεις για χρήση στη θεραπεία της ασθένειας αποθήκευσης γλυκογόνου τύπου II.
CY181101308T 2000-07-18 2018-12-07 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι CY1120977T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
EP14167882.1A EP2767291B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II
PCT/US2001/021651 WO2002005841A1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii
EP01951000A EP1301201B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii
EP07001091.3A EP1782825B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage diseases type II

Publications (1)

Publication Number Publication Date
CY1120977T1 true CY1120977T1 (el) 2019-12-11

Family

ID=22818451

Family Applications (2)

Application Number Title Priority Date Filing Date
CY181101308T CY1120977T1 (el) 2000-07-18 2018-12-07 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
CY20201100587T CY1123084T1 (el) 2000-07-18 2020-06-24 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100587T CY1123084T1 (el) 2000-07-18 2020-06-24 Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι

Country Status (18)

Country Link
US (10) US7056712B2 (el)
EP (4) EP3108895B1 (el)
JP (10) JP5113312B2 (el)
AT (1) ATE355075T1 (el)
AU (3) AU7194101A (el)
BR (1) BR0113006A (el)
CA (1) CA2416492C (el)
CY (2) CY1120977T1 (el)
DE (1) DE60126947T2 (el)
DK (5) DK3449934T3 (el)
ES (5) ES2277931T3 (el)
HK (3) HK1054690A1 (el)
LT (3) LT2767291T (el)
MX (1) MXPA03000474A (el)
PT (5) PT1782825E (el)
SI (3) SI2767291T1 (el)
TW (1) TWI280882B (el)
WO (1) WO2002005841A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2767291T (lt) * 2000-07-18 2016-11-25 Duke University Ii tipo glikogenozės gydymas
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) * 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
EP1587923B1 (en) * 2003-01-22 2011-08-24 Duke University Improved constructs for expressing lysosomal polypeptides
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CA2568150A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
JP2010509344A (ja) * 2006-11-13 2010-03-25 ザイストール セラピューティクス, インコーポレイテッド ポンペ病を治療するための方法
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
US20110223147A1 (en) 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
SI2318037T1 (sl) 2008-07-08 2015-07-31 Duke University Metoda za zdravljenje bolezni glikogenoze
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
US10017581B2 (en) 2013-02-20 2018-07-10 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
MX2015015560A (es) * 2013-05-15 2016-06-17 Univ Minnesota Transferencia de genes mediada por virus asociado a adeno para el sistema nervioso central.
CR20170107A (es) 2014-09-30 2017-09-01 Amicus Therapeutics Inc Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados
US11096991B2 (en) 2015-05-07 2021-08-24 The University Of Tokyo Nanoreactor using polyion complex polymersomes, and method for producing same
WO2017040647A1 (en) * 2015-08-31 2017-03-09 Duke University Methods and compositions for the treatment of cytopplasmic glycogen storage disorders
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
CA3010205A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
KR102455821B1 (ko) 2016-03-30 2022-10-18 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
WO2017173060A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
EP3452104A1 (en) 2016-04-15 2019-03-13 The Trustees of The University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
US11819539B2 (en) 2017-09-22 2023-11-21 The Trustees Of The University Of Pennsylvania Gene therapy for treating Mucopolysaccharidosis type II
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
CA2328518A1 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
EP1137762B1 (en) 1998-12-07 2008-10-08 Genzyme Corporation Treatment of pompe's disease
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
LT2767291T (lt) * 2000-07-18 2016-11-25 Duke University Ii tipo glikogenozės gydymas
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
JP2018199721A (ja) 2018-12-20
US20210169996A1 (en) 2021-06-10
US20020110551A1 (en) 2002-08-15
JP2016056206A (ja) 2016-04-21
JP2008081507A (ja) 2008-04-10
LT3449934T (lt) 2020-08-10
AU2010200487A1 (en) 2010-03-04
AU7194101A (en) 2002-01-30
JP2004503598A (ja) 2004-02-05
US20080175833A1 (en) 2008-07-24
PT1301201E (pt) 2007-03-30
EP2767291A3 (en) 2014-10-08
US7056712B2 (en) 2006-06-06
US8900552B2 (en) 2014-12-02
PT1782825E (pt) 2014-11-04
EP2767291B1 (en) 2016-09-14
US20120058132A1 (en) 2012-03-08
DE60126947D1 (de) 2007-04-12
JP2012006953A (ja) 2012-01-12
SI3449934T1 (sl) 2020-09-30
SI3108895T1 (sl) 2019-01-31
US20130195834A1 (en) 2013-08-01
US9370556B2 (en) 2016-06-21
EP3108895A1 (en) 2016-12-28
LT3108895T (lt) 2018-11-26
EP2767291A2 (en) 2014-08-20
CY1123084T1 (el) 2021-10-29
DK3449934T3 (da) 2020-06-29
ES2277931T3 (es) 2007-08-01
DK1782825T3 (da) 2014-11-03
ES2523024T3 (es) 2014-11-20
US20180185457A1 (en) 2018-07-05
US20150004152A1 (en) 2015-01-01
WO2002005841A1 (en) 2002-01-24
EP3449934B1 (en) 2020-05-20
DK3108895T3 (en) 2018-11-26
JP2020019822A (ja) 2020-02-06
CA2416492A1 (en) 2002-01-24
EP1301201B1 (en) 2007-02-28
ES2799882T3 (es) 2020-12-22
JP2018002749A (ja) 2018-01-11
JP2014185187A (ja) 2014-10-02
LT2767291T (lt) 2016-11-25
EP3449934A1 (en) 2019-03-06
HK1054690A1 (en) 2003-12-12
BR0113006A (pt) 2004-10-19
ES2700865T3 (es) 2019-02-19
DK1301201T3 (da) 2007-04-02
MXPA03000474A (es) 2003-10-06
DE60126947T2 (de) 2007-10-31
PT3449934T (pt) 2020-06-25
US9907839B2 (en) 2018-03-06
PT2767291T (pt) 2016-10-25
CA2416492C (en) 2008-04-29
US10792341B2 (en) 2020-10-06
EP1301201A1 (en) 2003-04-16
HK1103363A1 (en) 2007-12-21
US20100254966A1 (en) 2010-10-07
AU2001271941B2 (en) 2007-03-01
ATE355075T1 (de) 2006-03-15
EP3108895B1 (en) 2018-09-19
JP2017137357A (ja) 2017-08-10
JP5113312B2 (ja) 2013-01-09
DK2767291T3 (en) 2016-12-05
TWI280882B (en) 2007-05-11
US20050123531A1 (en) 2005-06-09
PT3108895T (pt) 2018-12-18
HK1197656A1 (zh) 2015-02-06
ES2599401T3 (es) 2017-02-01
SI2767291T1 (sl) 2016-11-30
JP2013231081A (ja) 2013-11-14
US20160184410A1 (en) 2016-06-30
JP6163216B2 (ja) 2017-07-12
JP5792774B2 (ja) 2015-10-14

Similar Documents

Publication Publication Date Title
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
DK1294379T3 (da) En hidtil ukendt anvendelse af deferipron
DE60142899D1 (de) Verbindungen für den transfer von oligonukleotiden
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
SE0100873D0 (sv) Method of treatment
EP1782825A3 (en) Treatment of glycogen storage diseases type II
DE60313344D1 (de) Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
EA200600318A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)